 |
|
Biomarkers of Endothelial Dysfunction and Risk of Type 2 Diabetes Mellitus
James B. Meigs, MD, MPH;
Frank B. Hu, MD, PhD;
Nader Rifai, PhD;
JoAnn E. Manson, MD, DrPH
JAMA. 2004;291:1978-1986.
ABSTRACT
| |
Context Endothelial dysfunction occurs in diagnosed type 2 diabetes mellitus but may also precede development of diabetes.
Objective To determine whether elevated plasma levels of biomarkers reflecting endothelial dysfunction (E-selectin; intercellular adhesion molecule 1 [ICAM-1]; and vascular cell adhesion molecule 1 [VCAM-1]) predict development of type 2 diabetes in initially nondiabetic women.
Design and Setting Prospective, nested case-control study within the Nurses' Health Study, an ongoing US study initiated in 1976.
Participants Of 121 700 women initially enrolled, 32 826 provided blood samples in 1989-1990; of those free of diabetes, cardiovascular disease, or cancer at baseline, 737 developed incident diabetes by 2000. Controls (n = 785) were selected according to matched age, fasting status, and race.
Main Outcome Measure Risk of confirmed clinically diagnosed type 2 diabetes by baseline levels of E-selectin, ICAM-1, and VCAM-1.
Results Baseline median levels of the biomarkers were significantly higher among cases than among controls (E-selectin, 61.2 vs 45.4 ng/mL; ICAM-1, 264.9 vs 247.0 ng/mL; VCAM-1, 545.4 vs 526.0 ng/mL [all P values  .004]). Elevated E-selectin and ICAM-1 levels predicted incident diabetes in logistic regression models conditioned on matching criteria and adjusted for body mass index (BMI), family history of diabetes, smoking, diet score, alcohol intake, activity index, and postmenopausal hormone use. The adjusted relative risks for incident diabetes in the top quintile vs the bottom quintiles were 5.43 for E-selectin (95% confidence interval [CI], 3.47-8.50), 3.56 for ICAM-1 (95% CI, 2.28-5.58), and 1.12 for VCAM-1 (95% CI, 0.76-1.66). Adjustment for waist circumference instead of BMI or further adjustment for baseline levels of C-reactive protein, fasting insulin, and hemoglobin A1c or exclusion of cases diagnosed during the first 4 years of follow-up did not alter these associations.
Conclusion Endothelial dysfunction predicts type 2 diabetes in women independent of other known risk factors, including obesity and subclinical inflammation.
INTRODUCTION
Type 2 diabetes mellitus is increasingly prevalent worldwide,1 conferring major burdens on health and health care costs. Type 2 diabetes may be largely preventable,2-3 but a comprehensive understanding of its etiology is still needed. Development of atherosclerotic cardiovascular disease (CVD) is the principal complication in type 2 diabetes, but clinical CVD can also precede development of diabetes,4 lending support to the hypothesis that diabetes and CVD share common antecedents. A syndrome of insulin resistance may constitute this common antecedent,5 but mechanisms unifying diverse effects of insulin resistance are not well defined. Insulin resistance is an established factor in the pathogenesis of type 2 diabetes but has an uncertain association with CVD.6
Subclinical inflammation could be a unifying factor because it is a precursor of CVD, is associated with insulin resistance, and precedes development of type 2 diabetes.7-8 Inflammatory mediators may be pathogenic by inducing systemic endothelial dysfunction. This hypothesis localizes insulin resistance and atherosclerosis to a unifying tissue type: in large arteries, endothelial dysfunction leads to clinical CVD, whereas in the capillary and arteriolar endothelium, with a vast surface area in intimate contact with metabolically active, insulin-sensitive tissues, endothelial dysfunction may lead to type 2 diabetes.9-10 Identification of endothelial dysfunction as a type 2 diabetes precursor might expand options for diabetes prevention and treatment.
Endothelial dysfunction can be detected by measurement of elevated plasma levels of cellular adhesion molecules (CAMs), including E-selectin, intercellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion molecule 1 (VCAM-1). Elevated levels of CAMs have been a consistent finding in cross-sectional studies of patients with type 2 diabetes11-12 and people at increased risk for diabetes.12-14 Retinal arteriolar narrowing, a marker of microvascular dysfunction, has been shown to predict incident type 2 diabetes,15 but prospective data directly linking endothelial dysfunction to development of diabetes remain sparse and inconsistent.16-17 In this study, we tested the hypothesis that elevated levels of E-selectin, ICAM-1, and VCAM-1 predict incident type 2 diabetes in women, independent of known diabetes risk factors, including obesity and subclinical inflammation.
METHODS
Study Participants
The Nurses' Health Study began in 1976, when 121 700 female nurses aged 30 to 55 years and from 11 US states responded to a questionnaire of health-related information. Questionnaires have been administered biennially to update health information and identify new cases of disease.
During 1989-1990, 32 826 women free of diagnosed diabetes, coronary heart disease, stroke, or cancer provided blood samples. By 2000, 737 of these women had developed type 2 diabetes. Controls providing baseline blood samples were matched to diabetes cases by year of birth, date of blood draw, race, and fasting status (at least 8 hours overnight) at blood draw. In addition, another control was matched on these characteristics and also on body mass index (BMI) to each of the most obese cases (cases in the top 10% of the BMI distribution). We matched the most obese cases on BMI to improve statistical control for obesity, seeking to ensure that differences in risk of diabetes were not a function of incomplete control of confounding by higher levels of obesity in diabetes cases. Thus, we analyzed a sample of 785 controls.
Women who provided blood samples had a higher prevalence of obesity, a higher prevalence of a family history of diabetes, and a lower prevalence of current smoking but were otherwise similar to women not providing blood. Subjects provided written informed consent, and the study was approved by the institutional review board of Partners HealthCare System, Boston, Mass.
Ascertainment of Diabetes
Baseline and incident type 2 diabetes were identified by self-report and confirmed by a validated supplementary questionnaire detailing symptoms, diagnostic laboratory test results, and diabetes treatment. Women were confirmed to have type 2 diabetes if they reported at least 1 of the following on the supplementary questionnaire: treatment with either insulin or an oral hypoglycemic agent, at least 1 classic symptom of diabetes (for instance, polyuria, polydipsia, weight loss) plus an elevated plasma glucose level, or an elevated plasma glucose level on 2 occasions. Elevated plasma glucose was defined as at least 140 mg/dL ( 7.8 mmol/L) fasting, at least 200 mg/dL (11.1 mmol/L) nonfasting, or at least 200 mg/dL (11.1 mmol/L) 2 hours after an oral glucose tolerance test for cases diagnosed before 1998; for cases diagnosed in 1998 and later, the fasting plasma glucose threshold was at least 126 mg/dL (7.0 mmol/L).18 Women were classified with incident diabetes if they met these criteria and were diagnosed at least 1 year after the date of blood collection. The validity of self-reported diabetes in this cohort has been confirmed with medical record review.19
Assessment of Diabetes Risk Factors
Every 2 years, exposure status has been updated by questionnaire, including smoking, menopausal status and use or nonuse of postmenopausal hormone therapy, and body weight. We calculated BMI (measured in 1988) as weight in kilograms divided by the square of height in meters. In 1986, we assessed self-reported waist girth. The presence or absence of a family history of diabetes in first-degree relatives was assessed in 1982 and 1988. Information about physical activity was obtained in 1980, 1982, 1986, 1988, and 1992. Diet and alcohol consumption were assessed in 1980, 1984, 1986, and 1990 by using semiquantitative food frequency questionnaires. Physical activity and diet exposures were calculated as updated cumulative average levels. The reproducibility and validity of the food-frequency questionnaires have been described.20 We summarized intake of cereal fiber, glycemic load, trans-fats, and the ratio of polyunsaturated to saturated fats (scored 1-5 for each, with 5 being the most healthy intake) to create a diet score (scored 4-20), with a high diet score associated with a reduced risk of type 2 diabetes.21 Reported weights have been shown to correlate with measured weights (r = 0.96); reported waist girth, with measured waist circumference (r = 0.89).22-23 Physical activity assessment has also been validated.24
Laboratory Procedures
Women providing blood samples were sent a phlebotomy kit, returning the sample by overnight mail in a frozen water bottle. On arrival, samples were processed and frozen in liquid nitrogen until analysis; 97% arrived within 26 hours of phlebotomy. Quality control samples were routinely frozen with study samples; the long-term stability of plasma samples collected and stored under this protocol has been documented.25 Study samples were analyzed in randomly ordered case-control pairs to further reduce systematic bias and interassay variation.
Levels of E-selectin, ICAM-1, and VCAM-1 were measured in 2002 by commercial enzyme-linked immunosorbent assay (R & D Systems, Minneapolis, Minn). These biomarkers are reliable markers of early atherosclerosis26 and have modest correlations (r = 0.04-0.58) with endothelial dysfunction assessed directly by brachial artery flow-mediated vasodilatation or microcirculation iontophoresis methods in a variety of populations.12, 27-29 C-reactive protein (CRP) levels were measured via a high-sensitivity latex-enhanced immunonephelometric assay (Dade Behring, Newark, Del). Insulin levels were measured by using a double antibody system with less than 0.2% cross-reactivity between insulin and its precursors (Linco Research, St Louis, Mo). Hemoglobin A1c was measured by immunoassay (Roche Diagnostics, Indianapolis, Ind). The coefficients of variation for analytes were E-selectin, 4.50% to 6.22%; ICAM-1, 3.56%; VCAM-1, 8.48% to 9.77%; CRP, 2.07% to 4.47%; fasting insulin, 3.52% to 11.7%; and hemoglobin A1c, 1.9% to 3.0%.
Statistical Analysis
We conducted a prospective, nested case-control analysis of endothelial dysfunction biomarkers as predictors of incident type 2 diabetes. We compared baseline characteristics of study women by using t tests,  2 tests, or Wilcoxon rank-sum tests. We used conditional logistic regression to account for correlations introduced by matching to estimate the relative risk and 95% confidence intervals (CIs) for levels of biomarkers predicting type 2 diabetes. We divided the distributions of E-selectin, ICAM-1, and VCAM-1 into quintiles according to the distribution in controls and used regression models to estimate the significance of trend in relative risk across increasing quintiles and to estimate risk of diabetes in each quintile relative to the lowest quintile.
Using nested regression models conditioned on matching for age, race, and fasting status, we estimated crude relative risks of diabetes; then adjusted for BMI, family history of diabetes, smoking, alcohol intake, diet score, physical activity, and hormone use; further adjusted for these covariates and levels of CRP; and finally simultaneously adjusted for all diabetes risk factors and biomarker levels. In these analyses, we had at least 85% power to detect a significant linear trend (2-sided P<.05) across quintiles in which the relative risk in the top quintile relative to the bottom was at least 1.5.30 In a subsidiary analysis among women providing fasting blood samples, we also adjusted nested regression models for levels of fasting insulin and hemoglobin A1c. We used SAS (version 6.12; SAS Institute Inc, Cary, NC) for all analyses and defined statistical significance as P<.05.
RESULTS
Women who developed type 2 diabetes during 10 years of follow-up were more obese, had a greater prevalence of a family history of diabetes, less alcohol use, a less favorable diet score, less physical activity, and a lower prevalence of hormone therapy use than did controls (Table 1). Levels of fasting insulin, hemoglobin A1c, E-selectin, ICAM-1, and VCAM-1 were all significantly higher at baseline in women who developed diabetes compared with those who remained nondiabetic at follow-up.
|
|
|
|
Table 1. Baseline Characteristics of Type 2 Diabetes Cases and Controls
|
|
|
Elevated levels of endothelial dysfunction biomarkers measured at baseline significantly increased the relative risk of incident diabetes. In analyses conditioned on matching for age, race, and fasting status, the relative risk of diabetes was 7.50 (95% CI, 5.05-11.14) in the highest quintile of E-selectin relative to the lowest quintile; for ICAM-1, the relative risk was 4.29 (95% CI, 2.95-6.23); and for VCAM-1, the relative risk was 1.54 (95% CI, 1.10-2.15) (Table 2, model 1). After adjustment for BMI, family history of diabetes, smoking, diet score, alcohol intake, activity index, and postmenopausal hormone use, elevated levels of E-selectin and ICAM-1 but not VCAM-1 remained significant predictors of incident diabetes (Table 2, model 2).
|
|
|
|
Table 2. Relative Risk of Type 2 Diabetes According to Baseline Levels of Endothelial Dysfunction Biomarkers
|
|
|
These results remained similar when waist circumference was used instead of BMI (as in model 2, Table 2) as an index of obesity: for E-selectin, the relative risk of diabetes in the highest quintile was 5.08 (95% CI, 3.05-8.47); for ICAM-1, 2.46 (95% CI, 1.50-4.03); and for VCAM-1, 1.05 (95% CI, 0.66-1.70). Inflammation may be involved in the association between endothelial dysfunction and risk of diabetes, but further adjustment of model 2 for levels of CRP did not eliminate associations of E-selectin and ICAM-1 with incident diabetes (Table 2, model 3). Cellular adhesion molecules may act independently or in a causal pathway leading to diabetes, but simultaneous adjustment for all 3 biomarkers and other diabetes risk factors (Table 2, model 4) did not eliminate associations of E-selectin and ICAM-1 with diabetes.
We conducted subsidiary analyses (Table 3) to ensure that the baseline sample was free of diabetes (by excluding women with baseline hemoglobin A1c levels >6.5%); that associations were not due to an effect of incipient diabetes on endothelial function (by excluding cases diagnosed during the first 4 years of follow-up); and that associations were not due to an effect of subclinical CVD at baseline (by excluding women with incident CVD during follow-up). Although blood pressure and plasma lipid levels have not been measured in this cohort, we attempted to account for their possible confounding effects by adjusting models for reported treatment for hypertension or hyperlipidemia. In all subsidiary analyses, levels of E-selectin and ICAM-1, but not VCAM-1, remained independent predictors of incident type 2 diabetes.
|
|
|
|
Table 3. Relative Risk of Type 2 Diabetes According to Baseline Levels of Endothelial Dysfunction Biomarkers, Excluding Possible Baseline Diabetes, Diabetes Diagnosed Early in Follow-up, Incident Cardiovascular Disease, or Adjusting for Hypertension and Hyperlipidemia*
|
|
|
Hyperinsulinemia and hyperglycemia are potent risk factors for type 2 diabetes and may mediate effects of endothelial dysfunction on diabetes risk. We assessed these effects in the subset of women providing fasting blood samples in models adjusted for diabetes risk factors and levels of hemoglobin A1c and fasting insulin (Table 4). In this analysis, elevated levels of E-selectin, but not ICAM-1 or VCAM-1, were still a significant independent predictor of incident type 2 diabetes.
|
|
|
|
Table 4. Relative Risk of Type 2 Diabetes According to Baseline Levels of Endothelial Dysfunction Biomarkers Among the Subset of Women With Known Hemoglobin A1c and Fasting Insulin Levels
|
|
|
Obesity and the mediating effects of increased adipocyte signaling could amplify the effect of endothelial dysfunction, increasing risk for type 2 diabetes. We assessed the joint effect of BMI and levels of E-selectin, ICAM-1, and VCAM-1 on risk of diabetes (Figure 1). BMI and endothelial dysfunction had only additive effects on diabetes risk: at every level of increasing BMI or E-selectin, there was a stepwise increase in the risk of diabetes. The most obese women with the highest levels of E-selectin had a 13.6-fold (P<.001) increased risk of diabetes relative to the leanest women with the lowest E-selectin levels. Patterns were similar for increasing levels of ICAM-1 and BMI (P = .02 for ICAM-1 at each level of BMI). Elevated levels of VCAM-1 did not substantially increase risk of diabetes at any level of BMI. In each of these analyses, P values for first-order biomarker x BMI interaction terms were not statistically significant.
|
|
|
|
Figure. Joint Effect of Body Mass Index (BMI) and Levels of Biomarkers of Endothelial Dysfunction on Risk of Type 2 Diabetes
BMI (calculated as weight in kilograms divided by the square of height in meters) has been divided into 3 categories; the distribution of biomarkers, into tertiles. The adjusted risk of diabetes among women in each category is shown relative to women with BMI <25 and with biomarker levels in the lowest tertile. Relative risks were conditioned on matching on age, race, and fasting status and were adjusted for BMI, C-reactive protein, family history of diabetes, smoking status, alcohol use, diet score, physical activity, and postmenopausal hormone use. ICAM-1 indicates intercellular adhesion molecule 1; VCAM-1, vascular cell adhesion molecule 1. Error bars represent 95% confidence intervals.
|
|
|
COMMENT
A fundamental concept underlying the insulin resistance syndrome is that there is some shared precursor to type 2 diabetes and CVD. Insulin resistance has been a plausible candidate for this common precursor, but specific mechanisms whereby insulin resistance leads to both diabetes and CVD remain ill defined. Systemic inflammation is associated with insulin resistance and incident CVD and diabetes.7-8,31-32 A specific mechanism whereby inflammation may contribute to these disease processes is induction of endothelial dysfunction,33 placing the vascular endothelium in the key unifying position in the shared pathogenesis of CVD and diabetes. Although there is prospective evidence linking endothelial dysfunction with incident CVD,34 previous prospective data linking endothelial dysfunction to risk of diabetes have been indirect and inconsistent.15-17 In this study, we demonstrated that elevated plasma levels of molecular biomarkers of endothelial dysfunction were predictors of incident diabetes in a large cohort of initially nondiabetic women. Elevated levels of E-selectin, ICAM-1, and VCAM-1 raised the relative risk of diabetes by 1.5- to 7.5-fold. Associations of E-selectin and ICAM-1 with diabetes were independent of the confounding effects of usual risk factors for diabetes, and E-selectin remained a powerful predictor even after the potentially mediating effects of obesity, inflammation, and levels of insulin and hemoglobin A1c were accounted for.
Subclinical tissue injury and increased fat mass elevate blood levels of inflammatory cytokines, especially tumor necrosis factor  and interleukin 6, which stimulate an acute-phase response marked by elevated levels of CRP.35 Localization of this inflammatory cascade by vascular endothelial cells is mediated by CAMs. Their surface expression is a common endothelial response to a variety of toxic stimuli, and their shedding into the systemic circulation provides evidence of endothelial cell activation and endothelial dysfunction.26 E-selectin, expressed exclusively by endothelial cells, is absent in inactive cells but is rapidly induced by inflammatory cytokines. ICAM-1 and VCAM-1 are expressed by endothelial cells and leukocytes in response to inflammatory cytokines, elevated levels of free fatty acids, oxidized low-density lipoprotein cholesterol, and advanced glycosylation end products occurring in diabetes.36 These CAMs facilitate leukocyte rolling, adhesion, and transmigration into the subendothelial space, key steps in the early formation of atherosclerotic plaque. Thus, elevated levels of CAMs represent an early marker of several pathogenic processes associated with endothelial dysfunction and the potential development of CVD and type 2 diabetes.
Impaired endothelial function in large arterial beds is a key step in the pathogenesis of CVD, and elevated levels of CAMs predict the incident development of CVD events independent of standard CVD risk factors.37 Endothelial dysfunction in the capillary and arteriolar microcirculation is a plausible key step in the evolution of tissue insulin resistance and may act by at least 2 mechanisms. Impaired endothelium-dependent vasodilatation and vasomotion may limit insulin-mediated capillary recruitment and microvascular redistribution of skeletal muscle blood flow from nonnutritive to nutritive flow routes, diminishing insulin delivery to metabolically active, insulin-sensitive muscle tissue.10, 38-40 Also, altered endothelial permeability impairs insulin delivery to the interstitium. In the dynamic state, interstitial insulin levels appear to be a rate-limiting step determining insulin effectiveness.41 In addition to vascular insulin resistance, endothelial dysfunction is associated with impaired fibrinolysis, microalbuminuria, impaired function of insulin-sensitive lipoprotein lipase (contributing to a dyslipidemia with high triglyceride and low high-density cholesterol levels), impaired fibrinolysis, and impaired endothelium-dependent nitric-oxide–mediated vasodilatation (contributing to hypertension), all features of the insulin resistance syndrome.9-10 Recent experimental evidence in humans has placed endothelial dysfunction in a direct link between blood pressure and insulin sensitivity.42 The results of our analysis extend observations linking endothelial dysfunction to CVD and its risk factors, strengthening support for the hypothesis that endothelial dysfunction is also an important precursor of type 2 diabetes.
Results of our study extend other evidence linking endothelial dysfunction to insulin resistance and risk of diabetes. Mice with endothelial dysfunction by virtue of targeted knockout mutations in the endothelium-dependent nitric oxide synthase gene are insulin resistant and display features of the insulin resistance syndrome.43 Endothelial dysfunction is a consistent finding in cross-sectional studies of established diabetes.11-12,44-45 Endothelial dysfunction and elevated levels of E-selectin, ICAM-1, and VCAM-1 have also been described in cross-sectional studies of nondiabetic subjects at increased risk of diabetes, including subjects with impaired glucose tolerance, and in nondiabetic first-degree relatives of patients with type 2 diabetes.12-14,46 Three previous epidemiologic studies have examined risk of incident diabetes. In the Atherosclerosis Risk in Communities (ARIC) Study, microcirculatory dysfunction, represented by retinal arteriolar narrowing, increased risk for diabetes by 71%, comparing subjects in the highest quartile of narrowing with those in the lowest quartile.16 Also in ARIC, levels of von Willebrand factor, another endothelial biomarker, was not an independent predictor of incident diabetes after BMI was accounted for, although coagulation factor VIII was an obesity-independent predictor of diabetes in women.16 In a study of 71 Pima Indians, elevated levels of several biomarkers, including E-selectin and ICAM-1, were not independently associated with incident diabetes.17 Treatment with drugs having beneficial effects on endothelial function also supports an association with insulin resistance and risk of diabetes. Insulin sensitization with troglitazone or metformin in type 2 diabetes lowers E-selectin levels, improves endothelium-dependent vasodilatation, and, when used in patients without diabetes, reduces risk of developing diabetes.3, 47-50 Therapy with statins51 or angiotensin-converting enzyme (ACE) inhibitors52 improves insulin sensitivity and endothelial dysfunction and, in secondary analyses of CVD prevention studies, has been associated with an approximately 30% reduced risk of incident diabetes.53-54 However, whether amelioration of endothelial dysfunction by using statins or ACE-based therapies will actually prevent type 2 diabetes remains to be confirmed in clinical trials.
Our study has several limitations. We assessed endothelial dysfunction solely by means of plasma biomarkers and do not have other measures of vascular physiology. However, although expression of CAMs represents a specific, early stage in the evolution of endothelial dysfunction, plasma levels have modest correlations with directly assessed endothelial function.12, 27-29 Our comprehensive assessment of diabetes risk factors allowed statistical control for important confounding factors in the pathogenesis of diabetes, but residual confounding could remain in the analysis. In particular, we did not measure levels of free fatty acids, atherogenic lipoproteins, or adipokines (for instance, adiponectin), known mediators of endothelial dysfunction and insulin resistance. Also, we measured only plasma insulin levels and did not have direct measurements of insulin resistance. Although plasma insulin levels in the physiologic range can induce insulin resistance in humans,55 statistical control for insulin levels attenuated but did not eliminate associations of E-selectin with incident diabetes. In addition, we were able to control for obesity only by using BMI or waist circumference because we did not have more precise measures of body fat percentage or fat distribution. However, for levels of E-selectin at least, the association with diabetes remained strong even after extensive covariate adjustment. Although residual confounding by incompletely measured or unmeasured physiologic covariates may exist in our models, it seems unlikely that more complete statistical adjustment would completely eliminate the observed associations.
In addition, although hyperglycemia may lead to endothelial dysfunction,56 our prospective study design and similar effects after subsidiary analyses excluding cases diagnosed during the first 4 years of follow-up or excluding women with hemoglobin A1c levels higher than 6.5% support the conclusion that endothelial dysfunction preceded development of diabetic hyperglycemia. Further, although undetected subclinical atherosclerosis (which occurs in prediabetes and is associated with elevated levels of CAMs) might explain the observed associations, removal of data for women with incident CVD during follow-up did not alter the results. These findings indicate that baseline endothelial dysfunction was not a consequence of undetected, coincident diabetes or atherosclerosis but was an early abnormality clearly preceding the subsequent development of type 2 diabetes. Finally, the analysis was conducted in relatively healthy white women aged 30 to 55 years (range, 41-67 years at baseline). Results may not be generalizable to women of other ages or ethnic backgrounds or to men.
In conclusion, we found that elevated plasma levels of biomarkers reflecting endothelial dysfunction were powerful independent predictors of type 2 diabetes in initially healthy women. Our findings support the hypothesis that endothelial dysfunction may be a common pathogenic precursor to CVD and type 2 diabetes, placing endothelial dysfunction as a fundamental abnormality in the insulin resistance syndrome. These findings may have important implications for the prevention and treatment of type 2 diabetes. Therapies that improve endothelial dysfunction may prove important in the treatment of insulin resistance and in strategies to slow the accelerating worldwide epidemic of type 2 diabetes and its costly, morbid complications.
AUTHOR INFORMATION
| |
Corresponding Author: James B. Meigs, MD, MPH, General Internal Medicine Unit, Massachusetts General Hospital, 50 Staniford St, Ninth Floor, Boston, MA 02114 (jmeigs{at}partners.org).
Author Contributions: Dr Meigs had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Meigs, Hu, Rifai, Manson.
Acquisition of data: Hu, Manson.
Analysis and interpretation of data: Meigs, Hu, Manson.
Drafting of the manuscript: Meigs.
Critical revision of the manuscript for important intellectual content: Meigs, Hu, Rifai, Manson.
Statistical expertise: Meigs, Hu, Manson.
Obtained funding: Meigs, Hu, Manson.
Administrative, technical, or material support: Meigs, Hu, Rifai, Manson.
Study supervision: Meigs, Hu, Rifai, Manson.
Funding/Support: This work was supported by research grants (DK36798, CA87969, DK46519, and DK58845 to Drs Manson and Hu) from the National Institutes of Health. Dr Meigs is supported by an American Diabetes Association Career Development Award.
Role of the Sponsors: The funding sources for this study played no role in the design or conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.
Acknowledgment: We are indebted to the participants in the Nurses' Health Study for their cooperation, to Maureen Ireland Johnston, RN, for assistance with diabetes validation, to Jeanne Sparrow, BA, for assistance with case and control selection and laboratory specimen preparation, and to Jessica Perhanidis, MPH, for assistance with the analysis.
Author Affiliations: General Medicine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School (Dr Meigs); Department of Nutrition, Harvard School of Public Health (Dr Hu); Department of Pathology, Children's Hospital Medical Center and Harvard Medical School (Dr Rifai); Division of Preventive Medicine and the Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, and the Department of Epidemiology, Harvard School of Public Health (Drs Hu and Manson), Boston, Mass.
REFERENCES
1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-1431.
ABSTRACT
2. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
FREE FULL TEXT
3. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
FREE FULL TEXT
4. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129-1134.
FREE FULL TEXT
5. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
ABSTRACT
6. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation. 1998;97:996-1001.
FREE FULL TEXT
7. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999;353:1649-1652.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
8. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334.
FREE FULL TEXT
9. Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes. 1997;46(suppl 2):S9-13.
PUBMED
10. Clark MG, Wallis MG, Barrett EJ, et al. Blood flow and muscle metabolism: a focus on insulin action. Am J Physiol Endocrinol Metab. 2003;284:E241-258.
FREE FULL TEXT
11. Albertini J, Valensi P, Lormeau B, Aurousseau M. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Diabetes Care. 1998;21:1008-1013.
ABSTRACT
12. Caballero AE, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 1999;48:1856-1862.
ABSTRACT
13. Vehkavaara S, Seppala-Lindroos A, Westerbacka J, Groop P-H, Yki-Jarvinen H. In vivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabetes Care. 1999;22:2055-2060.
FREE FULL TEXT
14. Balletshofer BM, Rittig K, Enderle MD, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation. 2000;101:1780-1784.
FREE FULL TEXT
15. Wong TY, Klein R, Sharrett AR, et al. Retinal arteriolar narrowing and risk of diabetes mellitus in middle-aged persons. JAMA. 2002;287:2528-2533.
FREE FULL TEXT
16. Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G. Factor VIII and other hemostasis variables are related to incident diabetes in adults: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 1999;22:767-772.
FREE FULL TEXT
17. Krakoff J, Funahashi T, Stehouwer CD, et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care. 2003;26:1745-1751.
FREE FULL TEXT
18. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes. 1997;20:1183-1197.
WEB OF SCIENCE
| PUBMED
19. Manson JE, Rimm EB, Stampfer MJ, et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet. 1991;338:774-778.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
20. Willett WC. Nutritional Epidemiology. New York, NY: Oxford University Press; 1990.
21. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345:790-797.
FREE FULL TEXT
22. Willett W, Stampfer MJ, Bain C, et al. Cigarette smoking, relative weight, and menopause. Am J Epidemiol. 1983;117:651-658.
FREE FULL TEXT
23. Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB, Willett WC. Validity of self-reported waist and hip circumferences in men and women. Epidemiology. 1990;1:466-473.
PUBMED
24. Hu FB, Sigal RJ, Rich-Edwards JW, et al. Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study. JAMA. 1999;282:1433-1439.
FREE FULL TEXT
25. Hankinson SE, London SJ, Chute CG, et al. Effect of transport conditions on the stability of biochemical markers in blood. Clin Chem. 1989;35:2313-2316.
FREE FULL TEXT
26. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med. 1999;107:85-97.
WEB OF SCIENCE
| PUBMED
27. Nawawi H, Osman NS, Annuar R, Khalid BA, Yusoff K. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis. 2003;169:283-291.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
28. Holmlund A, Hulthe J, Millgard J, Sarabi M, Kahan T, Lind L. Soluble intercellular adhesion molecule-1 is related to endothelial vasodilatory function in healthy individuals. Atherosclerosis. 2002;165:271-276.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
29. Brevetti G, Martone VD, de Cristofaro T, et al. High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilation in patients with peripheral arterial disease. Thromb Haemost. 2001;85:63-66.
WEB OF SCIENCE
| PUBMED
30. Chapman DG, Nam JM. Asymptotic power of chi square tests for linear trends in proportions. Biometrics. 1968;24:315-327.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
31. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51:1131-1137.
FREE FULL TEXT
32. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391-397.
FREE FULL TEXT
33. Hingorani AD, Cross J, Kharbanda RK, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation. 2000;102:994-999.
FREE FULL TEXT
34. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106:653-658.
FREE FULL TEXT
35. Yudkin JS, Stehouwer CDA, Emis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972-978.
FREE FULL TEXT
36. Gimbrone MAJ, Bevilacqua MP, Cybulsky MI. Endothelial-dependent mechanisms of leukocyte adhesion in inflammation and atherosclerosis. Ann N Y Acad Sci. 1990;598:77-85.
WEB OF SCIENCE
| PUBMED
37. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997;96:4219-4225.
FREE FULL TEXT
38. Baron AD. Cardiovascular actions of insulin in humans: implications for insulin sensitivity and vascular tone. In: Ferrannini E, ed. Insulin Resistance. London, England: Bailliere Tindall; 1994:961-985.
39. Serne EH, RG IJ, Gans RO, et al. Direct evidence for insulin-induced capillary recruitment in skin of healthy subjects during physiological hyperinsulinemia. Diabetes. 2002;51:1515-1522.
FREE FULL TEXT
40. Bonadonna RC, Saccomani MP, Del Prato S, Bonora E, DeFronzo RA, Cobelli C. Role of tissue-specific blood flow and tissue recruitment in insulin-mediated glucose uptake of human skeletal muscle. Circulation. 1998;98:234-241.
FREE FULL TEXT
41. Miles PD, Levisetti M, Reichart D, Khoursheed M, Moossa AR, Olefsky JM. Kinetics of insulin action in vivo: identification of rate-limiting steps. Diabetes. 1995;44:947-953.
ABSTRACT
42. Serne EH, Stehouwer CD, ter Maaten JC, et al. Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation. 1999;99:896-902.
FREE FULL TEXT
43. Duplain H, Burcelin R, Sartori C, et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation. 2001;104:342-345.
FREE FULL TEXT
44. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA. 2000;283:221-228.
FREE FULL TEXT
45. Hogikyan RV, Galecki AT, Pitt B, Halter JB, Greene DA, Supiano MA. Specific impairment of endothelium-dependent vasodilation in subjects with type 2 diabetes independent of obesity. J Clin Endocrinol Metab. 1998;83:1946-1952.
FREE FULL TEXT
46. Ferri C, Desideri G, Baldoncini R, et al. Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities. Diabetes. 1998;47:660-667.
ABSTRACT
47. Cominacini L, Garbin U, Fratta Pasini A, et al. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes. 1998;47:130-133.
ABSTRACT
48. Caballero AE, Saouaf R, Lim SC, et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism. 2003;52:173-180.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
49. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37:1344-1350.
FREE FULL TEXT
50. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796-2803.
FREE FULL TEXT
51. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2002;87:563-568.
FREE FULL TEXT
52. O'Driscoll G, Green D, Maiorana A, Stanton K, Colreavy F, Taylor R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1999;33:1506-1511.
FREE FULL TEXT
53. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357-362.
FREE FULL TEXT
54. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA. 2001;286:1882-1885.
FREE FULL TEXT
55. Arcaro G, Cretti A, Balzano S, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation. 2002;105:576-582.
FREE FULL TEXT
56. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care. 2003;26:1589-1596.
FREE FULL TEXT
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Flicker Light-Induced Retinal Vasodilation in Diabetes and Diabetic Retinopathy
Nguyen et al.
Diabetes Care 2009;32:2075-2080.
ABSTRACT
| FULL TEXT
Generalizability of dietary patterns associated with incidence of type 2 diabetes mellitus
Imamura et al.
Am. J. Clin. Nutr. 2009;90:1075-1083.
ABSTRACT
| FULL TEXT
Cytokine and Cytokine-Like Inflammation Markers, Endothelial Dysfunction, and Imbalanced Coagulation in Development of Diabetes and Its Complications
Goldberg
J. Clin. Endocrinol. Metab. 2009;94:3171-3182.
ABSTRACT
| FULL TEXT
Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease.
Nozaki et al.
J Am Coll Cardiol 2009;54:601-608.
ABSTRACT
| FULL TEXT
Insulin and Insulin-Like Growth Factor-I Receptors Differentially Mediate Insulin-Stimulated Adhesion Molecule Production by Endothelial Cells
Li et al.
Endocrinology 2009;150:3475-3482.
ABSTRACT
| FULL TEXT
Multiple Biomarker Prediction of Type 2 Diabetes
Meigs
Diabetes Care 2009;32:1346-1348.
FULL TEXT
ABO Blood Group and the Risk of Pancreatic Cancer
Wolpin et al.
JNCI J Natl Cancer Inst 2009;101:424-431.
ABSTRACT
| FULL TEXT
Cocoa consumption for 2 wk enhances insulin-mediated vasodilatation without improving blood pressure or insulin resistance in essential hypertension
Muniyappa et al.
Am. J. Clin. Nutr. 2008;88:1685-1696.
ABSTRACT
| FULL TEXT
Allopurinol Use Yields Potentially Beneficial Effects on Inflammatory Indices in Those With Recent Ischemic Stroke: A Randomized, Double-Blind, Placebo-Controlled Trial
Muir et al.
Stroke 2008;39:3303-3307.
ABSTRACT
| FULL TEXT
Vascular Inflammation, Insulin Resistance, and Reduced Nitric Oxide Production Precede the Onset of Peripheral Insulin Resistance
Kim et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:1982-1988.
ABSTRACT
| FULL TEXT
Alcohol Consumption, Mediating Biomarkers, and Risk of Type 2 Diabetes Among Middle-Aged Women
Beulens et al.
Diabetes Care 2008;31:2050-2055.
ABSTRACT
| FULL TEXT
Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study
Martinez-Gonzalez et al.
BMJ 2008;336:1348-1351.
ABSTRACT
| FULL TEXT
Tissue Plasminogen Activator, von Willebrand Factor, and Risk of Type 2 Diabetes in Older Men
Wannamethee et al.
Diabetes Care 2008;31:995-1000.
ABSTRACT
| FULL TEXT
Detection and characterisation of microcirculatory abnormalities in the skin of diabetic patients with microvascular complications
Brooks et al.
Diabetes and Vascular Disease Research 2008;5:30-35.
ABSTRACT
Overweight Latino Children and Adolescents Have Marked Endothelial Dysfunction and Subclinical Vascular Inflammation in Association With Excess Body Fat and Insulin Resistance
Caballero et al.
Diabetes Care 2008;31:576-582.
ABSTRACT
| FULL TEXT
Retinal Arteriolar Narrowing Predicts Incidence of Diabetes: The Australian Diabetes, Obesity and Lifestyle (AusDiab) Study
Nguyen et al.
Diabetes 2008;57:536-539.
ABSTRACT
| FULL TEXT
Cardiovascular Complications in Diabetes: Targets and interventions
Stirban and Tschoepe
Diabetes Care 2008;31:S215-S221.
ABSTRACT
| FULL TEXT
Endothelial Dysfunction and C-Reactive Protein Are Risk Factors for Diabetes in Essential Hypertension
Perticone et al.
Diabetes 2008;57:167-171.
ABSTRACT
| FULL TEXT
Blood pressure and risk of developing type 2 diabetes mellitus: The Women's Health Study
Conen et al.
Eur Heart J 2007;28:2937-2943.
ABSTRACT
| FULL TEXT
Inflammation and Endothelial Activation Is Evident at Birth in Offspring of Mothers With Type 1 Diabetes
Nelson et al.
Diabetes 2007;56:2697-2704.
ABSTRACT
| FULL TEXT
Multimarker Approach to Evaluate the Incidence of the Metabolic Syndrome and Longitudinal Changes in Metabolic Risk Factors: The Framingham Offspring Study
Ingelsson et al.
Circulation 2007;116:984-992.
ABSTRACT
| FULL TEXT
Microvascular Dysfunction in Obesity: A Potential Mechanism in the Pathogenesis of Obesity-Associated Insulin Resistance and Hypertension
Jonk et al.
Physiology 2007;22:252-260.
ABSTRACT
| FULL TEXT
Insulin Resistance: Link to the components of the metabolic syndrome and biomarkers of endothelial dysfunction in youth
Lee et al.
Diabetes Care 2007;30:2091-2097.
ABSTRACT
| FULL TEXT
Circulating Levels of Endothelial Adhesion Molecules and Risk of Diabetes in an Ethnically Diverse Cohort of Women
Song et al.
Diabetes 2007;56:1898-1904.
ABSTRACT
| FULL TEXT
Air pollution and inflammation in type 2 diabetes: a mechanism for susceptibility
O'Neill et al.
Occup. Environ. Med. 2007;64:373-379.
ABSTRACT
| FULL TEXT
Associations Between Lifestyle and Depressed Mood: Longitudinal Results From the Maastricht Aging Study
van Gool et al.
AJPH 2007;97:887-894.
ABSTRACT
| FULL TEXT
Relationship between Vascular Reactivity and Lipids in Mexican-Americans with Type 2 Diabetes Treated with Pioglitazone
Wajcberg et al.
J. Clin. Endocrinol. Metab. 2007;92:1256-1262.
ABSTRACT
| FULL TEXT
Interleukin-6 Impairs the Insulin Signaling Pathway, Promoting Production of Nitric Oxide in Human Umbilical Vein Endothelial Cells
Andreozzi et al.
Mol. Cell. Biol. 2007;27:2372-2383.
ABSTRACT
| FULL TEXT
Sex Differences in Endothelial Function Markers Before Conversion to Pre-Diabetes: Does the Clock Start Ticking Earlier Among Women?: The Western New York Study
Donahue et al.
Diabetes Care 2007;30:354-359.
ABSTRACT
| FULL TEXT
Does Hypoadiponectinemia Explain the Increased Risk of Diabetes and Cardiovascular Disease in South Asians?
Retnakaran et al.
Diabetes Care 2006;29:1950-1954.
FULL TEXT
Body Mass Index, Metabolic Syndrome, and Risk of Type 2 Diabetes or Cardiovascular Disease
Meigs et al.
J. Clin. Endocrinol. Metab. 2006;91:2906-2912.
ABSTRACT
| FULL TEXT
Systemic Immune Mediators and Lifestyle Changes in the Prevention of Type 2 Diabetes: Results From the Finnish Diabetes Prevention Study.
Herder et al.
Diabetes 2006;55:2340-2346.
ABSTRACT
| FULL TEXT
Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin
Diamanti-Kandarakis et al.
Hum Reprod 2006;21:1426-1431.
ABSTRACT
| FULL TEXT
Hemostatic Markers of Endothelial Dysfunction and Risk of Incident Type 2 Diabetes: The Framingham Offspring Study
Meigs et al.
Diabetes 2006;55:530-537.
ABSTRACT
| FULL TEXT
Elevated Markers of Endothelial Dysfunction Predict Type 2 Diabetes Mellitus in Middle-Aged Men and Women From the General Population
Thorand et al.
Arterioscler. Thromb. Vasc. Bio. 2006;26:398-405.
ABSTRACT
| FULL TEXT
Nut and Seed Consumption and Inflammatory Markers in the Multi-Ethnic Study of Atherosclerosis
Jiang et al.
Am J Epidemiol 2006;163:222-231.
ABSTRACT
| FULL TEXT
Diet and inflammation: a link to metabolic and cardiovascular diseases
Esposito and Giugliano
Eur Heart J 2006;27:15-20.
ABSTRACT
| FULL TEXT
Myocardial infarction and heart failure in the db/db diabetic mouse
Greer et al.
Am. J. Physiol. Heart Circ. Physiol. 2006;290:H146-H153.
ABSTRACT
| FULL TEXT
Urinary Albumin Excretion and Its Relation With C-Reactive Protein and the Metabolic Syndrome in the Prediction of Type 2 Diabetes
Brantsma et al.
Diabetes Care 2005;28:2525-2530.
ABSTRACT
| FULL TEXT
Dietary pattern, inflammation, and incidence of type 2 diabetes in women
Schulze et al.
Am. J. Clin. Nutr. 2005;82:675-684.
ABSTRACT
| FULL TEXT
Rapid Effects of Rosiglitazone Treatment on Endothelial Function and Inflammatory Biomarkers
Hetzel et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:1804-1809.
ABSTRACT
| FULL TEXT
Diet-quality scores and plasma concentrations of markers of inflammation and endothelial dysfunction
Fung et al.
Am. J. Clin. Nutr. 2005;82:163-173.
ABSTRACT
| FULL TEXT
Subclinical Inflammation and Vascular Dysfunction in Women with Previous Gestational Diabetes Mellitus
Heitritter et al.
J. Clin. Endocrinol. Metab. 2005;90:3983-3988.
ABSTRACT
| FULL TEXT
Effect of Intensive Glycemic Control on Levels of Markers of Inflammation in Type 1 Diabetes Mellitus in the Diabetes Control and Complications Trial
Schaumberg et al.
Circulation 2005;111:2446-2453.
ABSTRACT
| FULL TEXT
A Burning Question: Does an Adipokine-Induced Activation of the Immune System Mediate the Effect of Overnutrition on Type 2 Diabetes?
Tataranni and Ortega
Diabetes 2005;54:917-927.
ABSTRACT
| FULL TEXT
Endothelial-Dependent Vasodilation and Incidence of Type 2 Diabetes in a Population of Healthy Postmenopausal Women
Rossi et al.
Diabetes Care 2005;28:702-707.
ABSTRACT
| FULL TEXT
Recombinant Methionyl Human Leptin Administration to Achieve High Physiologic or Pharmacologic Leptin Levels Does Not Alter Circulating Inflammatory Marker Levels in Humans with Leptin Sufficiency or Excess
Chan et al.
J. Clin. Endocrinol. Metab. 2005;90:1618-1624.
ABSTRACT
| FULL TEXT
Microplate ELISAs for Soluble VCAM-1 and ICAM-1
Chang et al.
Annals of Clinical & Laboratory Science 2005;35:312-317.
ABSTRACT
| FULL TEXT
Developmental programming of the metabolic syndrome by maternal nutritional imbalance: how strong is the evidence from experimental models in mammals?
Armitage et al.
J. Physiol. 2004;561:355-377.
ABSTRACT
| FULL TEXT
|
